DBV Technologies (DBVT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

DBV Technologies

NasdaqCM•Healthcare•Biotechnology

$13.47-0.23(-0.02%)Market closed

Market Cap

$5.11B

P/S

1018.6x

P/B

31.9x

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

How this company scores

AverageMetricSide Score: 42/100

Strongest: Growth (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability6/25

Growth15/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Growing revenueInterest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1018.6x5y range 5.4x – 1448.7x

Currently above its 20-quarter median.

P/B · 31.9x5y range 1.0x – 243.6x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $5.11B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $5.02M
Q. Revenue: $700,000
TTM EBITDA: $-174.84M
TTM Op. Income: $-177.83M
Q. Op. Income: $-50.60M
TTM Net Income: $-175.99M
Q. Net Income: $-50.40M
EPS: $-0.12
Shares Out.: $433.54M

$5.02M in TTM revenue grew 32.0% YoY, reaching $700,000 last quarter. TTM EBITDA of $-174.84M and TTM operating income of $-177.83M show growth is flowing through to the bottom line. However, net income is negative at $175.99M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 32% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -7142.9%
Op. Margin: -7228.6%
Net Margin: -7200.0%

Op. margin of -7228.6% is down 4422.4% YoY — costs are rising relative to revenue. Net margin at -7200.0% Over the past year, operating margin is down 158% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1018.6x
P/B Ratio: 31.9x

P/S of 1018.6x and P/B of 31.9x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $223.20M
Cash: $174.90M
Long-Term Debt: N/A
Book Value: $160.40M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-52.60M
TTM Free Cash Flow: $-170.60M
FCF Margin: -3399.7%
FCF / Net Income: 1.0

TTM FCF of $-170.60M on $-52.60M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.